Clinical Trial Detail

NCT ID NCT02314117
Title A Study of Ramucirumab (LY3009806) in Combination With Capecitabine and Cisplatin in Participants With Stomach Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements yes
Sponsors Eli Lilly and Company
Indications

gastroesophageal junction adenocarcinoma

stomach cancer

Therapies

Capecitabine

Fluorouracil

Cisplatin

Ramucirumab

Age Groups: adult

Additional content available in CKB BOOST